Avascular Necrosis (Osteonecrosis) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Avascular necrosis (AVN), also known as osteoradionecrosis, aseptic necrosis, or ischemic bone necrosis, arises from a disruption in the blood supply to the bone, causing bone tissue to deteriorate. Blood, essential for delivering nutrients and oxygen to bones, becomes obstructed (avascular), leading to necrosis of bone tissue. This process weakens the bone and may eventually lead to its collapse. Joint proximity increases the risk of joint surface collapse, resulting in arthritis pain and inflammation. AVN can affect any bone but typically targets the ends (epiphysis) of long bones like the femur, resulting in hip and knee complications. Commonly affected areas include upper arm bones, shoulders, and ankles. While AVN can impact a single bone, it more frequently affects multiple bones concurrently (multifocal AVN). The severity of AVN's impact depends on the location and extent of bone involvement and the bone's ability to regenerate itself. Factors contributing to AVN include blockage, thickening, or weakening of blood vessels, often exacerbated by corticosteroid use during cancer treatment. The interruption of subchondral blood supply induces hypoxia, damaging cell membranes and causing cell necrosis, characterized by an influx of neutrophils and macrophages. Macroscopic manifestations include subchondral collapse and subsequent joint degeneration. MRI scans typically reveal osteosclerotic changes due to decreased bone resorption from disrupted osteoclast function. Specifically, the T2 signal increases, and the T1 signal decreases due to bone marrow fat cell edema/ischemia. Risk factors for AVN in corticosteroid-treated individuals include high-dose radiation to weight-bearing bones, orthovoltage radiation (prevalent before 1970), age over 10 at treatment, and sickle cell disease. Although AVN primarily occurs during cancer treatment, it can manifest post-treatment as well. Corticosteroids, frequently administered for leukemia, lymphoma, and chemotherapy-induced nausea/vomiting and brain swelling control, heighten AVN risk.

 

Thelansis’s “Avascular Necrosis (Osteonecrosis) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Avascular Necrosis (Osteonecrosis) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Avascular Necrosis (Osteonecrosis) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Avascular Necrosis (Osteonecrosis) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Avascular Necrosis (Osteonecrosis) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033